Actually, the approval of Rida for Sarcoma will BE a big event. Mr. Market is pretty smart. There are many individuals on the sidelines that refuse to invest in an oncology company without a product, and are waiting for a go-no go on Rida. They have figured out that approval will open the door to $500 million in royalities, and milestone payments to Ariad. The present value of that cashflow stream is worth much, much more than booking sales. This will sew the seeds in creating an independent, standalone oncology company.
News 
Market Data 
Discover 
AI
